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Abstract
Background: Metronidazole is the most commonly used drug for the treatment of giardiasis in humans. In spite of its
therapeutic efficacy for giardiasis, low patient compliance, especially in children, side effects, and the emergence of
metronidazole-resistant strains may restrict its use. Albendazole has been used to treat Giardia duodenalis infections in
recent years. However, efficacy studies in vivo and in vitro have produced diverse results as to its effectiveness. A moderately
benign side effect profile, combined with established efficacy against many helminths, renders it promising for treatment of
giardiasis in humans.
Methodology and Principal Findings: We performed a search in the PubMed, Scopus, EMBASE, the ISI Web of Science,
LILIACS, and Cochrane Controlled Trials Register for trials published before February 2010 as well as in references of relevant
research and review articles. Eight randomized clinical trials (including 900 patients) comparing the effectiveness of
albendazole with that of metronidazole were included in meta-analysis. After extracting and validating the data, the pooled
risk ratio (RR) was calculated using an inverse-variance random-effects model. Albendazole was found to be equally as
effective as metronidazole in the treatment of giardiasis in humans (RR 0.97; 95% CI, 0.93, 1.01). In addition, safety analysis
suggested that patients treated with albendazole had a lower risk of adverse effects compared with those who received
metronidazole (RR 0.36; 95% CI, 0.10, 1.34), but limitations of the sample size precluded a definite conclusion.
Conclusions/Significance: The effectiveness of albendazole, when given as a single dose of 400 mg/day for 5 days, was
comparable to that of metronidazole. Patients treated with albendazole tended to have fewer side effects compared with those
who took metronidazole. Given the safety, effectiveness, and low costs of albendazole, this drug could be potentially used as an
alternative and/or a replacement for the existing metronidazole therapy protocols in the treatment of giardiasis in humans.
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Introduction
Giardiasis in humans, caused by the protozoan parasite Giardia
duodenalis (syn. G. lamblia, G. intestinalis), is a common parasitic
disease [1]. The prevalence of infection is commonly between 2–
5% in the developed world and 20–30% in the developing and
underdeveloped countries [2]. Infection is initiated by ingestion of
cysts in contaminated drinking water and/or contaminated food
[1]. Ingested cysts release trophozoites which colonize and
replicate in the small intestine of the new host. G. duodenalis does
not invade the epithelial or deeper layers of the mucosa and
propagation takes place on the epithelial surface [3]. The
outcomes of Giardia infections vary significantly and the majority
of infections are self-limiting. Clinical manifestations range from a
relatively asymptomatic phase marked by mild nutrient malab-
sorption, to an ephemeral or persistent acute stage, with
steatorrhea, intermittent diarrhea, vomiting, malabsorption syn-
drome and weight loss, or to a subacute chronic phase that can
mimic gallbladder or peptic ulcer disease [4,5]. Infections in
immunocompetent individuals are generally self-limited, suggest-
ing the existence of effective host defense mechanisms against the
parasite [6]. Different diagnostic methods are employed for the
diagnosis of human giardiasis of which the most insensitive
method, direct stool microscopy is used routinely in developing
countries where the disease is endemic [5,7].
Existing chemotherapy protocols recommend that patients
should be treated if the parasite is found, irrespective of the
presence or absence of acute symptoms [8]. However, some
investigators question the usefulness of chemotherapy in infected
people in endemic areas due to the extremely high rate of
reinfection, as high as 90% in some studies [9,10]. Treatment
preferences vary among clinicians and in different locations.
www.plosntds.org 1 May 2010 | Volume 4 | Issue 5 | e682Several synthetic compounds (including metronidazole and other
nitroimidazole derivates such as albendazole, mebendazole,
furazolidone, tinidazole, ornidazole) are used in the treatment of
giardiasis in humans. A single dose of tinidazole (2.0 g) has been
shown to have a clinical efficacy of 80–100% in different clinical
trials [11,12] while the compliance is improved compared with
other giardiasis treatments. However, the high cost of tinidazole
may restrict its use in mass chemotherapy campaigns [13] in
developing and underdeveloped countries (e.g. $18 to $32 for a
single-dose of 2 g for the treatment of trichomoniasis). The most
widely used treatment protocols employ metronidazole given 3
times per day for 3–5 days [8,14,15,16]. Metronidazole is typically
administered in doses of 250 mg 3 times a day for 5–7 days for
adults and 15 mg/kg 3 times a day for 5–7 days in children.
However, albendazole is typically given as a single dose of
400 mg/day for 3–5 days. In recent years, therapeutic failure of
metronidazole, the first-line drug of choice in giardiasis in humans,
has increasingly been reported from all around the world [17].
Metronidazole is prescribed widely for a wide range of non-
parasitic infectious diseases; overusing metronidazole as a
treatment option for parasitic infections may increase the chances
of the development of clinically drug-resistant strains of Helicobacter
pylori, an important cause of gastric cancer in humans [18]. Low
compliance of patients with the current metronidazole therapy
protocols, the emergence of the metronidazole-resistant strains of
the parasite and other pathogens, and rapid reinfection of treated
patients in the endemic areas are additional reasons for
considering alternative therapies [19].
Treatment compliance is a key factor affecting the outcome of
giardiasis. However, compliance has been neglected in the
literature [20], and is therefore not part of the current analysis.
In one report on metronidazole use in patients with giardiasis,
treatment compliance was extremely poor because of missed doses,
spillage, inaccurate measuring implements, and poor adherence to
the prescribed frequency and duration of medication [21].
Common adverse reactions frequently reported with metronida-
zole include metallic taste, nausea, vomiting, diarrhea, and
epigastric discomfort [20]. Moreover, its activity against the host’s
normal intestinal microflora; its contraindication for children,
pregnant and breastfeeding women; and its carcinogenic and
tumorigenic properties in animal models make it less than optimal
for widespread use [8]. Finding safer drugs with less toxicity and
more effective therapeutic properties and developing novel
protocols (e.g fewer doses and shortened duration) to maximize
the effects of existing drugs are, therefore, crucial for the field.
Albendazole has been used extensively for the treatment of a
wide range of helminth parasites including hookworms, Ascaris
lumbricoides, Trichuris trichiura, Echinococcus sp.[22] and Taenia sp. [23]
with few side effects (reviewed by Keiser and Utzinger [24]). The
mechanism of action of albendazole differs from that of
metronidazole. While metronidazole affects electron transport of
the parasite [25], it is believed that albendazole exerts its anti-
giardial effects by interaction with tubulin of the Giardia
cytoskeleton [26]. Albendazole also has overt giardiacidal activity
in vitro [27], as well as being able to resolve infections in a mouse
model of G. duodenalis infection [19,26]. Using albendazole against
giardiasis in humans could potentially augment mass treatment
programs, which are part of helminth control campaigns, since
most patients with Giardia are probably co-infected with other
parasitic agents. Altogether, the evidence suggests that albendazole
could be considered as a potential anti-giardial agent. Its lower
toxicity, its relative insolubility and poor absorption from the gut,
and its lack of significant effects on the intestinal microflora could
make albendazole an ideal substitute for metronidazole. The aims
of the current meta-analysis, therefore, were first to address the
effectiveness and second to assess the safety of albendazole
compared with metronidazole for the treatment of giardiasis in
humans.
Methods
Data source and study selection
A literature search of the PubMed database (1966–February
2010), Scopus, EMBASE, the Cochrane Controlled Trials
Register (issue 4, 2009), LILIACS and the ISI Web of Science
for trials published before February 2010 was performed. The
literature search used the following terms: ‘‘giardiasis’’, ‘‘metroni-
dazole’’, and ‘‘albendazole.’’ The abstracts of all selected articles
were read to identify the potentially eligible articles. A manual
search was performed systematically using the authors’ reference
files and reference lists from original communications, selected
books and review articles [8,28]. Language restriction was not
applied. The contents of abstracts or full-text manuscripts
identified during our literature search were reviewed to determine
whether they met the criteria for inclusion. For inclusion, a study
had to allocate the study participants randomly to study groups (a
prospective randomized clinical trial). Included studies had to
compare the effectiveness of albendazole with that of metronida-
zole in the treatment of giardiasis.
Figure 1 summarizes the trial selection process. Our search
identified twenty-nine articles for further consideration, of which
only eight articles met the inclusion criteria. Major reasons for
exclusion of studies were duplicate publications from which only
one article was selected [29,30], animal models of infections
[19,26], studies of veterinary importance [31], studies in vitro [32],
single-arm studies with no randomized control groups [33], studies
lacking a comparison between the effectiveness of albendazole
with metronidazole [34], review articles [8,28], studies with no
clear randomization allocation procedure [35], studies using
albendazole and metronidazole analogues [36] as well as the
studies showing the synergistic effects between albendazole and/or
metronidazole with other drugs [37,38]. Conference proceedings
Author Summary
Giardiasis is one of the most common intestinal protozoal
infections worldwide. Although metronidazole is the most
common drug used to treat giardiasis in humans, its use is
associated with a variety of side effects. Poor compliance
and the emergence of metronidazole-resistant strains may
restrict use of the drug. Albendazole is an orally
administered broad-spectrum anthelmintic agent. The
use of albendazole has fewer side effects than metronida-
zole. The anthelmintic has been used against Giardia
duodenalis both in vivo and in vitro with different results.
However, the current meta-analysis assessed the effective-
ness and safety of albendazole compared with metroni-
dazole for the treatment of giardiasis in humans. After
searching different databases, eight comparative random-
ized clinical trials, including 900 patients, met our criteria
and were selected for the current meta-analysis. Results
showed that albendazole was as effective as metronida-
zole for the treatment of giardiasis in humans and people
receiving the drug tended to have fewer side effects
compared with those who received metronidazole. Given
the safety, effectiveness, and low costs of albendazole, this
drug may be considered a potential alternative and/or a
replacement for the existing widely used metronidazole in
the treatment of giardiasis in humans.
Albendazole for the Treatment of Human Giardiasis
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compared the effectiveness of albendazole with that of metroni-
dazole in the treatment of giardiasis [29,39–45]. Together these
articles followed 900 patients presenting with symptomatic and/or
asymptomatic G. duodenalis infections. Among these 900 treated
patients, 452 (50.2%) individuals were treated with albendazole
whereas 448 (49.8%) received metronidazole.
Data extraction and analysis
Data were extracted independently by two reviewers (SSM and
SMS) from the eight randomized controlled trials [Table 1 and
Table 2]. Discrepancies were resolved by discussion. Study
characteristics recorded were as follows: 1) first author’s name,
year of publication and country of origin; 2) description of the
population; 3) number of participants; 4) age and sex distribution
of the participants; 5) number of participants in each arm; 6)
clinical profile (symptomatic, asymptomatic infections); 7) the
follow-up period; 8) the outcome measure; 9) study design; 10) type
and dosage of the drugs; and 11) effectiveness range.
The primary outcome measure was parasitological cure defined
as the absence of parasites (trophozoites and/or cysts) in feces at
the end of the treatment in at least two consecutive stool
microscopy examinations. Parasitological cure was considered
necessary in order to evaluate the effectiveness of the treatment.
The secondary outcome measure, clinical cure, was defined as the
global improvement of clinical symptoms, such as diarrhea,
nausea/vomiting, transient abdominal pain and loss of appetite,
at the end of the follow-up period.
Assessment of study quality
The quality of included reports was compared using the Jadad
score which examines whether there is randomization, blinding,
and information on dropouts/withdrawals from the study [46]. It
also evaluates the appropriateness of randomization and blinding,
if present. The quality scale ranges from 0 to 5 points with a low-
quality report earning score of 2 or less. A study with a Jadad score
$3 is considered to be of ample quality. The quality of
parasitological diagnostic methods was assessed by the scoring
system utilized by Zaat et al. [47]. This method evaluates whether
techniques are sufficiently described and are adequate. Moreover,
this method evaluates the reproducibility of the parasitological
examinations and the level of inter-observer variation among
methods [Table 3].
Sensitivity analysis
Three different methods were employed to perform sensitivity
analysis of these trials. We first excluded the trial in which the
parasitological method employed was not clearly described [45].
Second, the trials that utilized the most insensitive diagnostic
methods, i.e. direct stool microscopy, alone were excluded [39,40].
Finally, we excluded a trial that used the most sensitive
parasitological methods (three methods at the same time) [41],
and compared the results with the remaining trials which used two
parasitological methods.
Data synthesis, statistical analysis
We identified eight randomized, controlled trials that reported
data on the comparison of the effectiveness of albendazole with
metronidazole in the treatment of giardiasis in humans. The
inconsistency across trials was calculated using the I
2 statistic;
results range between 0% (i.e., no observed heterogeneity) and
100% [48]. High values reflect increasing heterogeneity. Publica-
tion bias was assessed by means of funnel plots [49]. Relative risks
(RRs) were calculated for each study outcome separately based on
information presented in articles (i.e. the percentage of people
exhibiting parasitological cure in both groups relative to the
percentage of people continuing to shed cysts during the follow up
period); the pooled RRs and 95% confidence intervals (CIs) were
estimated by using the inverse-variance random-effects method
[50]. Although there is no standard description, an I
2 statistic
greater than 20% suggests heterogeneity while an I
2 statistic
greater than 50% usually is considered to represent significant
heterogeneity [48]. The statistical package Review Manager
Software 5 (Cochrane Collaboration, Oxford, UK) was used for
analyzing the data.
Results
Table 1 and Table 2 summarize the characteristics of the
randomized clinical trails (RCTs) included in the meta-analysis.
Studies were conducted in areas that are endemic for giardiasis in
humans, including Iran [39], Turkey [40,41], Mexico [42,44],
India [29,45] and Bangladesh [43]. Only one study [43] was rated
as having good methodological quality based on a Jadad score of 3
(see Table 3). However, because of the difficulty of comparing
different treatment protocols, one would rarely expect to achieve a
high Jadad score of 3 or greater. Only two studies [39,43] had at
least one blinded outcome measurement (parasitological cure);
whereas the other 6 trials were open label randomized clinical
trials (RCTs), allocating patients to albendazole and metronida-
zole groups randomly. Patients included in one of the groups in all
trials were given albendazole. The dosages of albendazole ranged
from 10 mg/kg sid for 5 days [41] to 400 mg/d for 5 days in most
trials; lengths of therapy ranged from a single dose for 1 day to 5
days. Metronidazole dosage ranged from 22.5 mg/day [29] to
1500 mg/day [40], and the treatment course varied from 5 to 7
days. In six studies, subjects had symptomatic and/or asymptom-
atic giardiasis while the clinical status of patients in one study [45]
was unclear. It is likely that the overwhelming majority, if not all,
of the cases included in the study of Hall and Nahar [43] were
Figure 1. Flow diagram deciphering the article selection
process for this meta-analysis study. Individual searches do not
add up to 56 as some of the same articles were retrieved by multiple
search engines.
doi:10.1371/journal.pntd.0000682.g001
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urban slum in Dhaka, Bangladesh was screened. The post-
treatment follow-up differed across the studies from 10 days
[39,43] to 21 days [29,42,45]. Loss of follow-up did not occur in
six studies whereas two articles [29,39] reported withdrawals and/
or dropouts. In one study [29], only 18/32 children in the
albendazole group and 16/32 children in the metronidazole group
finished the study, while in the other study, of 60 patients in each
arm 15 from the albendazole group and 9 from the metronidazole
group failed to complete the course of medication [39]. Side effects
from metronidazole therapy did not appear to influence the
treatment outcome, since low compliance in the latter study was
reported to be due to difficulties in returning to the study clinic
rather than to side effects of the treatments.
The included studies implemented different diagnostic proce-
dures alone or in combination with other parasitological methods.
As seen in Table 2, Yereli et al. [41] applied three different
parasitological methods at the same time (a parasitological
assessment score of 13 out of 15). Misra et al. [29], Romero-
Cabello et al. [42], and Nahar and Hall [43] employed two
different parasitological methods at the same time, Rodrı ´guez-
Garcı ´a et al. [44] used the Faust’s concentration method whereas
Alizadeh et al. [39] and Karabay et al. [40] utilized the least
sensitive parasitological method, conventional direct stool micros-
Table 1. Characteristics of the randomized controlled trials included in the meta-analysis.
Author, Year (Country) Study Design
No. of Randomized
Participants Age (yr)
Disease
Characteristics
Anti-giardial Drug
Regimens (No. of
Participants) Efficacy
Alizadeh, 2006 (Iran) [39] Open-label*, RCT 120 2–53 Symptomatic Albendazole, 400 mg/d
for 5d (60)
Albendazole (90%)
Two parallel arms Metronidazole, 250 mg
tid for 5d (60)
Metronidazole
(76.7%)
Yereli, 2004 (Turkey) [41] Open-label, RCT 107 3–15 Symptomatic Albendazole, 10 mg/kg
sid for 5d (52)
Albendazole
(90.4%)
Two parallel arms Asymptomatic Metronidazole, 20 mg/kg
tid for 7d (57)
Metronidazole
(89.1%)
Karabay, 2004 (Turkey) [40] Open-label, RCT 57 41612
¥ Symptomatic Albendazole, 400 mg/d
for 5d (28)
Albendazole
(96.4%)
Two parallel arms 38614
{ Metronidazole, 500 mg tid
for 5d (29)
Metronidazole
(100%)
Rodrı ´guez-Garcı ´a, 1996 [44] Open-label, RCT 49 3–12 Symptomatic Albendazole, 200 mg tid
for 5 d (27)
Albendazole (77%)
Two parallel arms Asymptomatic Metronidazole, 30 mg/kg
tid for 5 d (22)
Metronidazole
(72.7%)
Misra, 1995 (India) [29] Open-label, RCT 34 2–12 Symptomatic Albendazole, 400 mg/d
for 5d (18)
Albendazole (100%)
Two parallel arms Metronidazole, 7.5 mg/kg
tid for 5d (16)
Metronidazole
(100%)
Romero-Cabello, 1995
(Mexico) [42]
Open-label, RCT 100 4–11 Symptomatic Albendazole, 400 mg/d
for 5d (50)
Albendazole (94%)
Two parallel arms Asymptomatic Metronidazole, 7.5 mg/kg
tid for 5d (50)
Metronidazole
(98%)
Dutta, 1994 (India) [45] Open-label
&, RCT 150 2–10 N.S.
# Albendazole, 400 mg as a
single dose (75)
Albendazole (97%)
Multicenter, Two
parallel arms
Metronidazole, 22.5 mg/kg
tid for 5d (75)
Metronidazole
(97%)
Hall, 1993a (Bangladesh) [43] Open-label
1, RCT 283 5–10 N.S.
J Albendazole, 400 mg sid
for 3d (116)
Albendazole
(87.8%)
Three parallel arms in
each trial
Metronidazole, 125 mg tid
for 5d (115)
Metronidazole
(98.7%)
Hall, 1993b (Bangladesh) [43] Open-label
1, RCT 283 5–10 N.S.
J Albendazole, 400 mg sid
for 5d (115)
Albendazole
(94.1%)
Three parallel arms in
each trial
Metronidazole, 125 mg tid
for 5d (115)
Metronidazole
(100%)
Abbreviations: N.S., Not Stated; s.i.d., once a day; t.i.d., three times a day; RCT, randomized clinical trial.
¥Albendazole group.
{Metronidazole group.
#The included patients were probably symptomatic individuals referred to three hospitals in India.
JInitially 768 children were screened in an urban slum in Dhaka from which 678 children were found to be infected with Giradia. The infected children were probably
asymptomatic cyst-passers.
*The person who performed the stool microscopy was blinded to the treatments regimens.
&The stool sample examiner was blinded to the treatment regimens.
1Stool examination was done blinded to the treatment status of the patient.
doi:10.1371/journal.pntd.0000682.t001
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detectable G. duodenalis trophozoites and/or cysts in the stool
microscopy during the follow-up period was required to declare
the patients cured; five studies measured the outcomes solely based
on parasitological parameters [39,40,41,43,44], while three studies
applied both parasitological and clinical parameters for measuring
the outcomes [29,42,45].
Treatment effects were evaluated as relative risks (RR),
estimates that were calculated for each study individually based
on the incidence of undetectable infections among those taking
metronidazole compared to the incidence of undetectable cases
among those taking albendazole. Study-specific RRs were
combined using a random-effects model. The study-specific RRs
were weighted by the inverse of the sum of their variance and the
estimated between-studies variance component [50]. This method
calculates the mean difference between the treatment and control
groups, with SEM for the difference. There was no statistically
significant heterogeneity among these studies using the random
effects model (x
2=11.91, 8 degrees of freedom, P=0.16). An I
2 of
33% in the current meta-analysis suggests moderate heterogeneity.
Results demonstrated no differences between the effectiveness of
albendazole compared with metronidazole for treatment of
infections with G. duodenalis (RR, 0.97; 95% CI, 0.93 to 1.01).
When analysis was restricted to trials with a Jadad score of less
than 3 (seven trials, 617 patients), inconsistency between the trials
was low (I
2=0%), although the overall estimates remained almost
constant (RR, 0.99; CI, 0.96 to 1.03). Individual analyses of the
eight studies demonstrated that three studies [39,41,44], showed a
relative risk of greater than 1 for being cured after albendazole
therapy (Figure 2). These differences showed that albendazole
produced more apparent cures compared with metronidazole. In
one study [45], the relative risk was 1 indicating no differences
Table 2. Follow-up, outcomes assessment and relative risk in the trials included in the meta-analysis.
Author, Year (Country)
Follow-up
Duration
(days)
Outcome
Measure
Parasitological
Methods Used for
Assessing The
Outcomes
Relative RiskH (95%
Confidence Interval) Comments
Alizadeh, 2006 (Iran) [39] 10 P Direct iodine-stained
wet preparations
1.17 (1.00, 1.38) 15 patients from the albendazole group
and 9 patients from the metronidazole
group failed to complete the course of
medication
Yereli, 2004 (Turkey) [41] 14 P Direct saline-lugol wet
preparations
Formalin-acetate
concentration method
Trichrome staining
methods
1.01 (0.89, 1.15) No side effects were reported for
patients treated with either albendazole
or metronidazole during therapy
Karabay, 2004 (Turkey) [40] 15 P Direct iodine-stained
wet preparations
0.96 (0.88, 1.06) Individuals with pre-existing conditions
such as pregnant women were
excluded from the study
Rodrı ´guez-Garcı ´a, 1996 [44] 14 P Faust’s concentration
method
1.07 (0.77, 1.48) -
Misra, 1995 (India) [29] 21 P, C Direct saline wet
preparations
Formalin-ether
concentration method
0.95 (0.81, 1.11) Only 18/32 and 16/32 children in the
albendazole and metronidazole groups,
respectively finished the study. At the
end of follow-up period, the Giardia
cysts were found in the stool of a child
in the albendazole group
Romero-Cabello, 1995 (Mexico)
[42]
21 P, C Direct saline wet
preparations
Flotation methods
0.96 (0.89, 1.04) -
Dutta, 1994 (India) [45] 21 P, C Not clearly stated 1.00 (0.95, 1.05) Children having grade I and II
malnutrition, acute febrile disease and
those who had received medication for
giardiasis were excluded from the study
Hall, 1993a (Bangladesh) [43] 10 P Direct saline wet
preparation
Formalin-ether
concentration method
0.89 (0.81, 0.97) In Hall, 1993 a, b, the authors calculated
the treatment efficacy rates in patients
with first infections vs. reinfection
separately. To make the results
comparable to what was done
previously [Zaat et.al, 1997], we
included the first-infection cases,
excluding the single-dose regimens and
reinfection cases
Hall, 1993b (Bangladesh) [43] 10 P Direct saline wet
preparation
Formalin-ether
concentration method
0.94 (0.88, 1.01) See above.
Abbreviations: P, parasitological; C, clinical cure.
HRelative risks were calculated separately for each study outcome using the software Rev Man5.
doi:10.1371/journal.pntd.0000682.t002
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However, four studies [29,40,42,43], showed a relative risk less
than 1 (ranging from 0.89 to 0.96) indicating that metronidazole
was more effective (Figure 2). As illustrated in figure 2, the 95%
confidence intervals for these studies overlapped to a large degree,
suggesting that albendazole and metronidazole are equally
effective for treatment of giardiasis.
Further examination of the two-phase study carried out by Hall
and Nahar [43] showed that by increasing the duration of therapy
with albendazole from 400 mg/d for 3 days (in the first phase) to
400 mg/d for 5 days (in the second phase) the RR increased from
0.89 to 0.94. This suggests that when duration of treatment is
similar there is less of a difference between albendazole and
metronidazole therapy. Additionally, the efficacy of albendazole in
the treatment of giardiasis increased in the second phase of the
same study (94.1%) compared with the first phase of the trial
(87.8%), implying the need for using albendazole for longer
periods of time.
Publication bias and sensitivity analysis
Publication bias was examined using a funnel plot. Figure 3
plots the funnel plot of the treatment effects estimated from
individual studies on the x-axis (RR) and the standard error of
these estimates on y-axis (S.E [log RR]). This analysis shows that
the included studies were almost evenly distributed around the
vertical axis, providing no evidence of publication bias. To explore
further the possibility of heterogeneity due to the use of different
outcome measures, we confined our analysis to trials which used
Table 3. Internal validity (methodological and parasitological) of included trials.
Trial Methodological Assessment (Jadad Score)
1 Parasitological Assessment
¥
Ran-
domized
J?
Double-
Blinded?H
A Description
of Withdrawals
or Dropouts?
Total
Jadad
Score Description Adequate Repeated Interobserver Total
Alizadeh, 2006 [39] 1 0 1 2 2 0 3 0 5
Yereli, 2004 [41] 1 0 1 2 2 8 3 0 13
Karabay, 2004 [40] 1 0 1 2 2 0 3 0 5
Rodrı ´guez-Garcı ´a, 1996 [44] 1 0 0 1 2 3 3 0 8
Misra, 1995 [29] 1 0 1 2 2 3 3 0 8
Romero-Cabello, 1995 [42] 1 0 1 2 2 3 3 0 8
Dutta, 1994 [45] 1 0 1 2 2 0 3 0 5
Hall, 1993a,b [43] 2 0 1 3 2 4 3 0 9
1Range 0–5 (5 exemplifies articles with the highest quality).
¥Range 0–15, (15 indicates most optimal diagnostic procedure employed).
JRepresents generation of allocation sequence.
HRepresents allocation concealment.
doi:10.1371/journal.pntd.0000682.t003
Figure 2. Forest plot showing the effects of albendazole and metronidazole on human giardiasis. Relative risk was calculated for each
study separately. n/N=number described as cured over number of participants completing study.
doi:10.1371/journal.pntd.0000682.g002
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that used the most sensitive methods (three methods at the same
time). Similarly, we performed an analysis restricted to those
studies with clearly defined outcome measures. As seen in Table 4,
the overall estimates were equal and the confidence intervals were
comparable among these restricted data sets, as well as with the
combined meta-analysis values.
Adverse effects
Insixstudies,side effectsrelated to therapy wereabsentor were less
prominent in the patients receiving albendazole. Only in one study
[43] were the reported side effects more evident in patients in the
albendazole group compared with those in the metronidazole group
(40 cases vs. 7 cases; P,0.005). Overall, metallic taste and anorexia
were the mostcommonlyobserved side effects in patients treated with
metronidazole, while loose stools and abdominal pain were more
frequent among patients receiving albendazole. Most side effects were
transient and no trials were discontinued because of severe adverse
effects. In Yereli et al. [41], no side effects were reported in patients
treated with either albendazole or metronidazole. The report by
Rodrı ´guez-Garcı ´a et al. [44] does not mention if treated children
showed any side effects. In order to perform a safety analysis, the two
latter studies were excluded from the analysis. Hall and Nahar [43]
reported the adverse effectsofa two-stage trial, and thesewere treated
as a single trial. Considering all side effects together, 61 of 373
(16.3%) patients treated with albendazole and 82 of 371 (22.1%) of
patients treated with metronidazole experienced at least a single side
effect. The estimated summary RRs showed that individuals treated
with albendazole had a lower risk of adverse effects (RR 0.36)
compared with those who took metronidazole, but with a wide
confidence interval (95% CI, 0.10, 1.34) that included the null value.
Discussion
The major finding of this analysis is that when albendazole was
given as a single dose of 400 mg/day for 5 days it was as effective
as metronidazole in the treatment of giardiasis in humans.
Additionally, albendazole had statistically the same safety profile
as metronidazole.
Metronidazole has been widely used to treat giardiasis in
humans [10,38,51,52,53,54], and often causes side effects such as
nausea, metallic taste, dizziness and headache [8]. In addition, this
drug is a known mutagen in bacteria [55,56], it is genotoxic to
human cells [57,58] and it has been shown to be carcinogenic in
animal models [59,60]. However, there is no evidence showing
metronidazole is also carcinogenic in humans [60]. Typically,
metronidazole is administered in doses of 250 mg 3 times a day for
5–7 days for adults and 15 mg/kg 3 times a day for 5–7 days in
children. Some clinicians tend to use single-dose regimens, while
others like to administer higher dosages for an extended period of
time. The latter is problematic in developing countries, as
medications are frequently purchased in quantities which
represent less than a single day’s dose and effective therapies of
short duration are preferable [61]. The need for an extended
period of time for the treatment of giardiasis again may in part
explain the frequent side effects associated with metronidazole
therapy. Extended treatment with albendazole also appears to be
more effective than shorter duration protocols. However, the once
Figure 3. Funnel plots of included studies. The pooled estimate of log-RR for all trials is shown with a dashed vertical line.
doi:10.1371/journal.pntd.0000682.g003
Table 4. Sensitivity-analysis of the effect of the quality of
methods implemented for the measurement of
parasitological cure.
Method No. of Patients Pooled RR (95% CI)
A 900 0.97 (0.93, 1.01)
B 750 0.96 (0.92, 1.01)
C 524 0.94 (0.91, 0.98)
D 417 0.93 (0.90, 0.98)
A, all eight studies included [29,39–45].
B, one study with unclear outcome measure excluded [45].
C, studies using a single diagnostic method excluded [39,40].
D, one study which used the most sensitive methods excluded [41].
doi:10.1371/journal.pntd.0000682.t004
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day required for metronidazole therapy.
A further complication when using metronidazole therapy to
treat giardiasis is that the consumption of alcohol should be
avoided by patients during systemic metronidazole therapy and for
at least 24 hours after completion of treatment [62,63]. Taking
metronidazole and alcohol may result, rarely, in a disulfiram-like
reaction (nausea, vomiting, flushing, and tachycardia). It should be
noted that the consumption of alcohol by patients was not
monitored in any of the studies considered in the current meta-
analysis. Alcohol uptake could potentially explain side effects in
some patients receiving metronidazole. The lack of placebo-
controlled trials makes it difficult to attribute the existence and
severity of side effects to either of these two drugs. However, one
study that did not meet our inclusion criteria suggested that
patients receiving a placebo control presented with minimal side
effects [10]. Together, these limitations can potentially restrict the
use of metronidazole, in the treatment of giardiasis in humans.
In the trials included in the current meta-analysis, only one study
[39] clearly described the inclusion of both adults and children (2–
53 yr), while other studies exclusively included either only adults [40]
or only children [29,41,42,43,44,45]. The inclusion of different age-
groups potentially allows us to assess the effectiveness of treatment
and to ascertain the extent to which side effects occur in different age-
groups. Similarly, including patients with diverse clinical presenta-
tions (i.e. asymptomatic, symptomatic; acute, subacute, chronic) in
clinical trials could give us the opportunity to evaluate the effect(s) of a
given chemotherapy agent/protocol on patients with different clinical
manifestations. From the information presented in the articles, it
seems that only three articles [41,42,44] included both symptomatic
and asymptomatic patients, although the clinical status of patients
who participated in the study of Hall and Nahar [43] and Dutta et al.
[45] was not clear. Including patients from different age-groups and
with different clinical presentations in future studies would allow
investigators to analyze whether albendazole has a differential effect
that correlates to the disease clinical profile and/or age of the patient.
Our analysis suggests that the study designs typically used for
evaluating these drugs could be improved. Open-label trials may
be suitable for comparing two extremely similar treatments to
verify which one is more effective. Only Alizadeh et al. [39] and
Hall and Nahar [43] used an adequate protocol for concealing the
treatment protocol while determining the parasitological outcome.
The six other trials either did not specify or were insufficient in
using blinded observers to determine the outcome. Since
albendazole and metronidazole may produce certain side effects
specific to each drug and since these two drugs may be available in
different forms, the use of homogenous therapy regimens and/or
using blinded studies may be warranted in future clinical trials.
Several factors may influence the effectiveness of a particular
therapy. Nutritional and physiological conditions such as pre-
gnancy and immunodeficiency could potentially alter the effective-
ness of a specific drug as shown for other parasitic diseases
[64–67]. Individuals with ‘‘pre-existing’’ nutritional and physiological
(pregnant women) complications were excluded in only two studies
among those we have analyzed [40,45]. Dutta et al. [45] excluded
children having grade I and II malnutrition, patients with acute
febrile illness and those on long term drug therapy; while Karabay
et al. [40] excluded pregnant women and patients with fever from the
study. In future studies, it would be desirable to include only patients
with no known nutritional, physiological or immunological problems.
Resistance of G. duodenalis strains to metronidazole and other
drugs has been reported both in vitro and in vivo [8,68,69]. Misra
et al. [29] reported a 100% cure rate in groups treated with either
metronidazole or albendazole, while the other seven reported an
effectiveness of 72.7–100% for metronidazole and 77–97% for
albendazole. At least part of the so-called ‘‘failure-to-treat’’ cases
might be attributed to the presence of ‘‘drug-resistant’’ strains, a
mechanism to which none of the studies referred as a potential
reason for treatment failure. The use of different combinations of
albendazole with other anti-parasitic agents in future studies may
be desirable in order to minimize the risk of the emergence of
drug-resistant strains. However, the design of placebo-controlled
double blinded clinical trials may help us to better understand the
most appropriate regimen(s) and the most suitable chemotherapy
protocols.
Some limitations in the current analysis should be considered
before making definitive conclusions. First, the small number of
trials and patients included in the current analysis (8 studies, 900
patients) led to wide confidence intervals that rendered some of the
results inconclusive [70]. Second, publication bias is constantly a
potential pitfall in meta-analyses. While we did not try to trace
unpublished data for the current meta-analysis, our analysis failed
to detect any suggestion of such bias (Figure 3). Third,
heterogeneity among studies is another potential limitation to
our meta-analysis. It might be argued that differences in the
methods used for measuring the outcome of treatment could result
in differences in the reported parasitological cure rates, as some
combined methods are more sensitive than others. As seen in
Table 4, the effect sizes remained fairly constant in these analyses,
suggesting that heterogeneity due to diverse outcome measures
probably did not adversely affect our analyses. Performing
repeated microscopy-based stool examinations on at least two
consecutive occasions is sensitive enough to detect up to 95% of
infections [71 72]. This could potentially explain why we did not
see any difference among studies employing diverse methods since
all the studies required at least two consecutive negative stool
examinations before considering the patients cured.
The high rate of side effects from metronidazole therapy for
giardiasis, combined with the global emergence of resistant strains,
led us to consider the effectiveness of alternative treatments. This
meta-analysis revealed that albendazole cures Giardia infections
with the same effectiveness as metronidazole. However, we were
not able to show conclusively, due to limitations of the sample size,
that its toxicity profile is more favorable than metronidazole.
Therefore, we conclude that larger, double-masked, randomized
controlled trials of albendazole and metronidazole with uniform
outcome measures are needed to shed light on this important
clinical question.
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